Bio-Reference Laboratories, Inc. Reports Best Quarterly Revenues and Earnings in Corporate History with 25% Increase in Earnings Per Share

The Company continues to show solid results for all financial metrics including cash flow and DSO’s

ELMWOOD PARK, N.J.--()--(Except for Per Share Data or where otherwise noted, numbers are in thousands) Bio-Reference Laboratories, Inc. (NASDAQ: BRLI) announced that the Company recorded current quarter revenues of $172,302, an increase of 16% over the $148,029 recorded in the third quarter, fiscal year 2011. Net income after taxes in Q3FY11 was $12,596 resulting in fully diluted earnings per share (EPS) of $.45, up 25% and 25% respectively from the prior fiscal year third quarter net income after taxes of $10,081 and EPS of $.36. Gross profit on revenues for the current quarter was $86,049 resulting in a margin for gross profit on revenues of 50%, versus the $73,432, and 50%, reported for the prior fiscal year third quarter. Revenue per patient for the third quarter of the current fiscal year was $85.65, an increase of 2% over the $84.20 reported for the same quarter of the prior fiscal year. The number of patients served increased 14% to 1,997 in the current quarter from the prior year third quarter total of 1,745. The Company further noted that Days Sales Outstanding (DSO) were 79 days compared to the prior fiscal year same period when the DSO were 92 days. Cash flow from operations for the current fiscal quarter was just short of $13,000 compared to approximately $1,300 for the same period in the last fiscal year.

Nine-month revenues increased to $485,609, an increase of 19% over the same period revenues of $407,345 in the prior fiscal year (nine month numbers from 2011 are based on pro forma numbers which exclude non-operating gains and a loss). Net income after taxes for the first nine months of the current year was $29,267 resulting in an EPS of $1.05; this was an increase of 32% from the prior year same period net income after taxes of $22,137 which resulted in an EPS of $.79. The Company reported gross profit on revenues for the current nine month period of $236,772, resulting in a margin for gross profit on revenues of 49% compared to the prior year same period of $195,876 which resulted in a margin of 48%. The number of patients served increased 17% to 5,762 in the first nine months of the current year from the prior year same period total of 4,917. Cash flow from operations for the nine month period was over $36,000 compared to about $11,500 for the same period in the last fiscal year.

Marc D. Grodman, MD, CEO, commented: "BioReference has demonstrated what we believe to be a strong track record of growth and expansion for more than two decades. We are extremely pleased to report another successful quarter of earnings, growth and innovation. During the first half of the current fiscal year we introduced OnkoMatch, Inherigen and GenCerv – ground breaking new services in oncology and Women’s Health that were several years in development. We believe that these new offerings will pave the way for our continued growth and expansion. Innovation in science, in reporting and in providing information to our customers, have enabled us to maintain steady growth. GeneDx, our genetics laboratory, continues to lead the way for the development and introduction of innovation and pioneering testing services in genetic sequencing."

Dr. Grodman further noted: "This year, we have transitioned by moving innovative new services out of development mode and into implementation mode. We have been able to maintain our focus on additional new services and programs that we will be announcing over the next few months that we believe will further insure our continued growth in the future. In our industry, we face many challenges that will define us in the future. BioReference has positioned itself on the side of preserving a competitive environment for all laboratories, promoting technology and innovation for not only better health care but for providing more information to clinicians for lower costs. The healthcare landscape is evolving and we expect that our actions and initiatives will continue to flourish as these changes to our industry unfold. BioReference is fully engaged and prepared for the changes that are on the horizon."

Dr. Grodman continued: "Make no mistake about BioReference: we are a national laboratory with a national presence. We have a great deal of business in the New York region, but we derive an even greater portion of our revenues from the specialty markets that we serve across the country. We are able to grow because of our national footprint and our ability to introduce our service, support and technology innovation throughout the country. We developed our clinical strategy in the NorthEast, but we have successfully implemented it throughout the country. We understand that we provide a service and our ability to tailor that service to the individual markets we serve has enabled us to re-affirm our guidance that we gave earlier in the year of an increase Iin net revenues by more than 15% and net income by around 20% for Fiscal Year 2012.

The Company's third quarter earnings conference call has been scheduled to take place this morning, August 30, 2012 at 10:30 a.m. Eastern Daylight Time. The live audio cast will be available at the Company's corporate Website, www.bioreference.com and through www.streetevents.com. To listen to the call please go to either Website ten minutes before the conference call is scheduled to begin. You will need to register as well as download and install any necessary audio software. The Web cast will be archived, on both Websites, for 30 days following the call.

About BioReference Laboratories, Inc.

BRLI is a clinical testing laboratory offering testing, information and related services to physician offices, clinics, hospitals, employers and governmental units. We believe that we are the fourth largest full-service laboratory in the United States and the largest independent regional laboratory in the Northeastern market. BRLI offers a comprehensive list of laboratory testing services utilized by healthcare providers in the detection, diagnosis, evaluation, monitoring and treatment of diseases. BRLI primarily focuses on esoteric testing, molecular diagnostics, anatomical pathology, women’s health and correctional health care.

Bio-Reference Laboratories, Inc.
Statements of Operations
(Dollars in Thousands Except Per Share Data)
(Unaudited)
 
Three Months Ended

July 31,

2012   2011
Net Revenues $ 172,302   $ 148,029
Cost of Sales 86,253 74,597
Gross Profit on Revenues 86,049 73,432
General and Administrative 63,375 55,023
Operating Income 22,674 18,409
Other Expense, Net 492 416
Income Before Taxes 22,182 17,993
Taxes 9,586 7,912
Net Income 12,596 10,081
Income Per Share $ 0.45 $ 0.36
Number of Shares 27,695,215 27,941,233
Income Per Share (Diluted) $ 0.45 $ 0.36
Number of Shares (Diluted) 27,887,765 28,147,179
 
  Nine Months Ended
July 31,
2012   Pro Forma 2011***   Actual 2011
Net Revenues $ 485,609   $ 407,345   $ 407,345
Cost of Sales 248,837 211,469 211,469
Gross Profit on Revenues 236,772 195,876 195,876
General and Administrative 184,044 155,437 155,437
Operating Income 52,728 40,439 40,439
Other Expense, Net 1,179 1,103 (5,553 )
Income Before Taxes 51,549 39,336 45,992
Taxes 22,282 17,199 20,109
Net Income 29,267 22,137 25,883
Income Per Share $ 1.05 $ 0.79 $ 0.93
Number of Shares 27,754,771 27,915,189 27,915,189
Income Per Share (Diluted) $ 1.05 $ 0.79 $ 0.92
Number of Shares (Diluted) 27,930,202 28,123,558 28,123,558
 

***Pro Forma excludes gain from NJ Sales Tax Refund, loss from sale of aircraft and NY State Tax refund.

Bio-Reference Laboratories, Inc.
Balance Sheets
(Dollars in Thousands)
(Unaudited)
   
July 31, October 31,
2012   2011
Cash & Cash Equivalents $ 20,238 $ 22,013
Accounts Receivable (Net) 147,546 148,060
Plant, Property & Equipment (Net) 50,001 43,567
Intangible Assets (Net) 29,871 30,312
Other Assets 50,961 39,307
Total $ 298,617 $ 283,259
 
Accounts Payable $ 39,998 $ 38,612
Revolving Note 5,074 18,632
Long-Term Debt 18,993 15,250
Other Liabilities 20,264 20,998
Shareholder’s Equity 214,288 189,767
Total $ 298,617 $ 283,259
 

Statements included in this release that are not historical in nature, are intended to be, and are hereby identified as “forward-looking statements”. Statements looking forward in time are included in this release pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks and uncertainties that may cause the Company’s actual results in future periods to be materially different from any future performance suggested herein.

www.bioreference.com

Contacts

Bio-Reference Laboratories, Inc.
Delores Bowman, 201-791-2600
Acting Investor Relations Coordinator
201-791-1941 (fax)
dbowman@bioreference.com

Release Summary

Bio-Reference Laboratories, Inc. reports best quarterly revenues and earnings

Sharing

Contacts

Bio-Reference Laboratories, Inc.
Delores Bowman, 201-791-2600
Acting Investor Relations Coordinator
201-791-1941 (fax)
dbowman@bioreference.com